A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Status:
Recruiting

Trial end date:
2023-04-21

Target enrollment:

Participant gender:

The goal of the study is to evaluate the efficacy and safety of crizanlizumab in SCD patients with priapism.

Phase 2

Novartis Pharmaceuticals